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Summary. Background: Acetyl-salicylic acid (ASA) hyporesponsiveness occurs transiently after coronary artery bypass graft (CABG) surgery and may compromise the effectiveness of ASA in reducing thrombotic graft failure. A reduced response to ASA 81 mg once-daily after CABG surgery is overcome by four times daily ASA dosing. Objectives: To determine whether ASA 325 mg oncedaily or 162 mg twice-daily overcomes a reduced response to ASA 81 mg once-daily after CABG surgery. Methods: Adults undergoing CABG surgery were randomized to ASA 81 mg once-daily, 325 mg once-daily or 162 mg twice-daily. The primary outcome was median serum thromboxane B 2 (TXB 2 ) level on postoperative day 4. We pooled the results with those of our earlier study to obtain better estimates of the effect of ASA 325 mg once-daily or in divided doses over 24 h. Results: We randomized 68 patients undergoing CABG surgery. On postoperative day 4, patients randomized to receive ASA 81 mg once-daily had a median day 4 TXB 2 level of 4.2 ng mL À1 (Q1, Q3:
1.5, 7.5 ng mL À1 ), which was higher than in those randomized to ASA 162 mg twice-daily (1.1 ng mL
À1
; Q1, Q3: 0.7, 2.7 ng mL À1 ) and similar to those randomized to ASA 325 mg once-daily (1.9 ng mL À1 ; Q1, Q3: 0.9, 4.7 ng mL À1 ). Pooled data showed that the median TXB 2 level on day 4 in groups receiving ASA 162 mg twice-daily or 81 mg four times daily was 1.1 ng mL À1 compared with 2.2 ng mL À1 in those receiving ASA 325 mg oncedaily. Conclusions: Multiple daily dosing of ASA is more effective than ASA 81 mg once-daily or 325 mg once-daily at suppressing serum TXB 2 formation after CABG surgery. A twice-daily treatment regimen needs to be tested in a clinical outcome study.
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Background
Despite the routine use of acetyl-salicylic acid (ASA), about 40% of patients undergoing coronary artery bypass graft (CABG) surgery have at least one blocked graft within 12 months of surgery [1] . Most early graft failures are believed to be a result of thrombotic occlusion [2] . There are at least two potential reasons why thrombotic occlusions occur despite ASA treatment. The first is that the effectiveness of ASA in suppressing thromboxane A 2 production is reduced because some patients have an increase in their platelet turnover during the first week after CABG surgery [3, 4] . The second is that mechanisms other than platelet thromboxane A 2 production lead to thrombotic graft occlusion [2] . Acetyl-salicylic acid prevents the formation of thromboxane A 2 by irreversibly acetylating platelet cyclooxygenase 1 (COX-1). Despite having a half-life of only 20 min, ASA 81 mg once-daily markedly inhibits thromboxane A 2 production for up to 24 h in patients with normal platelet turnover because COX-1 activity is normally restored at a rate of about 10% per day as young non-aspirinated platelets enter the circulation [5] . However, during the first week after CABG surgery, platelet turnover is increased [4] and a larger percentage of young non-aspirinated platelets enters the circulation daily, thereby potentially overcoming the anti-aggregating effect of aspirin.
We have previously shown that ASA 81 mg once-daily incompletely inhibits serum thromboxane B 2 (TXB 2 ) production during the first week after CABG surgery [3] . TXB 2 is the stable metabolite of thromboxane A 2 and elevated urinary TXB 2 levels are an independent risk factor for early vein graft failure after CABG surgery [6] . We showed that ASA 81 mg four times daily and ASA 325 mg once-daily are more effective than ASA 81 mg once-daily in inhibiting TXB 2 after CABG surgery [3] . We posited that with an increased frequency of administration, ASA is able to acetylate the young platelets that escape the effects of a single 81 mg dose of the drug. Further, we proposed that the higher ASA dose improved aspirin non-responsiveness after CABG because it acetylated newly budding platelets on the surface of megakaryocytes in the bone marrow. [7] Our results with the multiple daily dosing regimen supported our hypothesis for the mechanism of aspirin non-responsiveness post-CABG. However, it is inconvenient to administer a drug four times over 24 h. We therefore decided to repeat the study by comparing ASA 325 mg in two divided doses (162 mg twice-daily) with once-daily regimens of 81 and 325 mg dosing.
We conducted a randomized controlled trial to determine whether a twice-daily ASA dose regimen overcomes the impaired response to ASA 81 mg once-daily in post-CABG patients and is also more effective than ASA 325 mg once-daily.
Methods

Study design
We performed a single-center randomized trial in patients undergoing CABG surgery with or without valve surgery at the Hamilton General Hospital. Our study was approved by the Research Ethics Board at Hamilton Health Sciences and all patients provided written informed consent.
Patients
Patients were eligible for inclusion if they were undergoing elective or urgent CABG (+/À valve surgery) on cardiopulmonary bypass. Exclusion criteria included: (i) initial platelet count <100 9 10 9 /L; (ii) moderate or severe liver disease; (iii) moderate or severe renal impairment (estimated creatinine clearance [CrCl] <30 ml min drainage >200 mL h À1 for 6 h); and (vi) refusal by patient or physician to provide consent.
Study procedures
Eligible patients were identified by our research coordinator/study nurse and the study explained and informed consent obtained. Eligible, consenting patients were then randomized in an open 1 : 1 : 1 fashion to receive ASA 81 mg once-daily, 162 mg twice-daily or 325 mg once-daily within 6 h of patient arrival in the intensive care unit (ICU). The randomization sequence was computer generated by research personnel not directly involved with the study and stratified by use of ASA within 48 h prior to surgery. Allocation concealment was maintained by research personnel at our research center who were not directly involved in this research project. Treatment allocation was not blinded but we made every effort to prevent investigators, other healthcare providers, those conducting data analysis and those carrying out the laboratory assays from becoming aware of treatment allocation. Once patients arrived in the ICU following surgery, they were given ASA 325 mg within 6 h of arrival irrespective of their treatment group allocation. Patients began their respective treatment regimens for the study drug on postoperative day 1 (day of surgery = day 0) and continued on study medication until postoperative day 7 or discharge from hospital, whichever occurred first. Patients were discharged home on ASA 81 mg once-daily according to usual practice.
Outcome measures
The primary outcome was the serum TXB 2 level on postoperative day 4. We also measured daily platelet counts and arachidonate-induced platelet aggregation by light transmission aggregometry (LTA) on postoperative day 4.
Sample collection and processing
Blood samples were collected into serum (no additive) and citrate-containing vacutainer tubes prior to the first dose of ASA on each postoperative day. For recovery of serum, blood was subjected to centrifugation at 200 9g for 10 min at 22°C and the serum was stored in aliquots at À20°C until analyzed. Blood collected into vacutainer tubes containing 3.2% sodium citrate was subjected to centrifugation at 120 9g for 5 min to recover platelet-rich plasma for LTA and then at 850 9g for 10 min to recover platelet-poor plasma. The platelet-rich plasma and platelet-poor plasma were stored at room temperature and used within 30 min as per assay protocol.
Laboratory analyses
Serum TXB 2 was measured using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA)
according to the manufacturer's instructions. These assays were performed by technologists who were blinded to study drug allocation. Platelet aggregation was measured in response to 1 mmol L À1 arachidonate. Aggregation was recorded for 6 min and was reported as the area under the curve (aggregation units 9 min).
Statistical analyses
Our sample size calculation indicated that 20 patients per group would provide 90% power to detect a 20% difference in serum TXB 2 among treatment groups. Therefore, we chose a final sample size of 60 patients. Our Research Ethics Board deemed our experimental therapy to be associated with negligible risk of harm, and thus, we were not obliged to maintain a Data Safety Monitoring Board. Descriptive statistics were used for all baseline variables, with means and standard deviations for normally distributed continuous variables, medians and interquartile ranges for non-normally distributed continuous variables, and rates and proportions for categorical variables.
Laboratory outcomes were compared among treatment groups using the Wilcoxon (non-parametric) test because the data were not normally distributed. Statistical significance was defined as a two-sided P-value of less than 0.05.
Pooled analysis
To obtain better estimates of the effect of ASA 325 mg given once-daily or in divided doses over 24 h we combined the results of the present study with those of our earlier study [3] , which had an identical design but randomized patients in an open 1 : 1 : 1 fashion to receive ASA 81 mg once-daily, 81 mg four times daily or 325 mg once-daily. The baseline characteristics of patients in our earlier study [3] and current study are comparable (Table 4) . We combined data for groups receiving ASA 325 mg once-daily, for the groups receiving ASA 81 mg once-daily and for those receiving ASA 325 mg per day in divided doses, either 162 mg twice-daily or 81 mg four times daily.
Results
Patients
Patient recruitment and randomization is illustrated in Fig. 1 . We randomized 68 patients between June 2013 and March 2014. Day 4 data were available in 60 patients who were all receiving the assigned treatment and were included in our final analysis. The baseline characteristics were similar amongst the three treatment groups. The mean age of the patients was 65 years and 88% were male. The median number of bypass grafts was four and the mean time on cardiopulmonary bypass was 1.7 h.
Medication compliance
We collected information on compliance with the ASA dosing regimens by monitoring nursing notes and the patients' medication administration records. We defined compliance as the extent to which patients successfully received their prescribed ASA doses at the correct dosing intervals, based on their treatment allocation. Our data indicate that compliance with the b.i.d. regimen was 88% and compliance with the o.d. regimen was 99% in the 81 mg o.d. group and 90% in the 325 mg o.d. group. There was a difference in the number of patients receiving the initial 325 mg ASA loading dose amongst the three treatment groups (Table 1) . Excluding those few patients who did not receive the loading dose of ASA did not change our results.
Platelet counts
The median baseline (preoperative) platelet count was 229 9 10 9 /L (quartile [Q]1, Q3: 192 9 10 9 /L, 285 9 10 9 / L). Postoperatively, there was an initial fall in platelet count followed by a rise to levels higher than those at baseline (Table 2 
Serum thromboxane B 2
Daily median serum TXB 2 levels are presented in Table 2 according to randomized treatment allocation. Figure 3 demonstrates serum TXB 2 levels for each of the three treatment groups. In all three groups, median TXB 2 levels reached a nadir on postoperative day 1-2, indicating approximately normal aspirin responsiveness for these first 2 days. After postoperative day 2, serum TXB 2 levels in patients treated with ASA 81 mg once-daily began to rise (coinciding with a rise in platelet count) relative to levels in the other two treatment groups.
On postoperative day 4, the median serum TXB 2 level in the group receiving ASA 162 mg twice-daily was lower than that in patients receiving ASA 81 mg once-daily (1.1 ng mL
À1
; Q1, Q3: 0.7 ng mL À1 , 2.7 ng mL À1 ; and, 4.7 ng mL À1 ; Q1, Q3: 1.5, 7.5 ng mL À1 , respectively; P = 0.0171) and similar to that in patients treated with ASA 325 mg once-daily (1.9 ng mL À1 ; Q1, Q3: 0.9, 4.7 ng mL À1 ; P = 0.3243) ( Table 2) . These results remain consistent after normalizing serum thromboxane levels to platelet count, whereby, on postoperative day 4, ASA 162 mg twice-daily more effectively suppressed the adjusted serum thromboxane levels than ASA 81 mg once-daily (0.006 ng mL À1 per plt; Q1, Q3: 0.003, 0.01 ng mL À1 per plt; and, 0.02 ng mL À1 per plt; Q1, Q3: 0.01, 0.04 ng mL À1 per plt, respectively; P = 0.007) and was similar to ASA 325 mg once-daily (0.09 ng mL À1 per plt; Q1, Q3: 0.003, 0.01 ng mL À1 per plt; P = 0.55).
Light transmission aggregation
On postoperative day 4, median arachidonate-induced platelet aggregation measured by light transmission aggregation (LTA) was similar in patients treated with ASA 162 mg twice-daily (7%; Q1, Q3: 4%, 8%) and those treated with ASA 81 mg once-daily (8%; Q1, Q3: 4%, 10%; P = 0.1583) and ASA 325 mg once-daily (5%; Q1, Q3: 4%, 7%; P = 0.5312) ( Table 3) .
Relationship between serum TXB 2 levels and platelet counts
Although the fall and rise in serum TXB 2 and postoperative platelet counts followed a similar pattern, there was no statistical association between them.
Pooled analysis
The pooled analysis in which we combined the results of the current study with those of our earlier study [3] is shown in Table 4 
Conclusions
Our study has two major findings. The first is that ASA 162 mg twice-daily almost completely suppresses TXB 2 levels during the first week after CABG surgery. The second is that ASA 325 mg given in divided doses produces greater suppression of TXB 2 levels than when given in a once-daily dose. Our results suggest that twice-daily ASA is a suitable regimen for a clinical outcomes study to evaluate whether preventing ASA hyporesponsiveness after CABG surgery can prevent premature graft failure and associated cardiovascular events. Our findings extend those of our earlier study in which we compared the effects of ASA 81 mg once-daily, 81 mg four times daily and 325 mg once-daily on postoperative TXB 2 levels in the first week after CABG surgery [3] . We cannot directly compare the effects of our twice-daily ASA regimen with the four times daily regimen tested in our previous study [3] but both were more effective than ASA 81 mg once-daily and median TXB 2 levels with the two regimens were similar (ASA 162 mg twice-daily, 1.07 ng mL À1 ; ASA 81 mg four times daily, 1.09 ng mL À1 ). In both studies, ASA 325 mg given in divided doses appeared to be more effective than ASA 325 mg once-daily, and ASA 325 mg once-daily appeared to be more effective than ASA 81 mg once-daily, although in this study these differences were not statistically significant. The most likely reason why ASA 325 mg once-daily suppresses TXB 2 levels more effectively than ASA 81 mg once-daily is that the higher dose also acetylates megakaryocytes in the bone marrow before platelets are released [7] .
Our study has some limitations. Firstly, we chose serum TXB 2 levels for our primary outcome because our study was not powered for clinical outcomes. Although there is no high-quality evidence that greater suppression of TXB2 translates into benefits for patients, observational studies have shown an association between urinary TXB2 levels and postoperative graft failure [6] , as well as myocardial infarction, stroke and CV death in patients receiving ASA for long-term secondary prevention [8] . Secondly, we did not adjust for multiple comparisons when performing secondary analyses. Consequently, the results of our analyses should be considered exploratory. Thirdly, platelet transfusions have the potential to affect TXB 2 levels, but the half-life of serum TXB 2 is short (minutes) and all platelet transfusions were administered intraoperatively. Thus it is unlikely that platelet transfusions would materially impact our results on postoperative day 4. Fourthly, we recognize that treatment allocation was not blinded, but we ensured that all but those at the bedside administering the ASA were blinded. Further, even if investigators and others became aware of treatment allocation, the risk of bias is low because the primary outcome was laboratory based (serum thromboxane levels) and therefore objective. Lastly, pooling the results of our studies given their size and number (only two studies) has its inherent limitations. There is also limited statistical power to explore heterogeneity between only two small studies. Nevertheless, we believe pooling is valid because the baseline characteristics are comparable, as is the approach to cardiac surgery at this single institution. Acetyl-salicylic acid is the only treatment that has been shown to prevent graft failure after CABG surgery [9] [10] [11] [12] [13] [14] [15] but despite its use, more than 40% of patients have at least one failed graft by 1 year after surgery [1] . Graft failure confers a 10-fold increase in the risk of major adverse cardiovascular events [1] and an alternative ASA dosing regimen that prevents premature graft failure could substantially reduce the risk of major adverse cardiovascular events. The results of our study support the choice of a twice-daily ASA dosing regimen for testing in future clinical outcome studies. ASA, acetyl-salicylic acid; CABG, coronary artery bypass graft; IU, international units; n, number; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
